# Epigeneron

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epigeneron

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.epigeneron.com
- Total disclosed funding: $5.3M
- Latest round: Series B (Mar 9, 2021)
- Investors on record: 3

## About

Based in Tokyo, Japan, Epigeneron, Inc. specializes in biopharmaceutical solutions, focusing on innovative therapies for diverse medical conditions, including oncology and autoimmune diseases.Epigeneron, Inc. is engaged in developing biopharmaceutical products that target specific cellular pathways to enhance therapeutic efficacy. Founded in 2015 in Tokyo, Japan, the company has completed a total of 4 deals, including a Series B funding round in March 2021, raising JPY 48 million from TOHOKU University Venture Partners, culminating in a total amount raised of JPY 48 million and a current valuation of JPY 2665.409 million. Tetsuya Mishima serves as the CEO of the company.Epigeneron specializes in advanced biopharmaceutical solutions, focusing primarily on developing innovative therapies for various medical conditions. The company’s core product offerings include proprietary drug candidates designed to target specific cellular pathways, thereby enhancing therapeutic efficacy and reducing side effects. These products aim to address unmet medical needs in areas such as oncology, autoimmune diseases, and regenerative medicine. The end users of these products are primarily healthcare providers and patients seeking novel treatment options. Epigeneron serves a diverse client base that includes hospitals, research institutions, and specialized clinics across North America, Europe, and parts of Asia, where their products are deployed in clinical settings and research applications.Epigeneron generates revenue through a combination of direct sales and partnerships with healthcare institutions. The transaction structure typically involves B2B engagements, where healthcare providers procure the company’s therapeutics for use in patient care and clinical trials. Specific pricing plans for the products are determined based on the therapeutic indications and the complexity of the treatments offered. Flagship products may be sold under specialized contracts or licensing agreements, reflecting their innovative nature and the value they provide within the healthcare ecosystem. The company’s revenue model is supported by ongoing collaborations with pharmaceutical firms and research entities, which further establish its financial viability in the competitive biopharmaceutical market.Epigeneron, Inc. plans to leverage its recent Series B funding of JPY 48 million, raised in March 2021, to support the growth strategy of its pharmaceutical business. The company is focused on designing and launching new products aimed at addressing critical healthcare needs, though specific release dates have not been disclosed. Epigeneron is also targeting expansion into new geographic markets in North America and Europe by 2023, aiming to increase its footprint and serve a larger patient population.

## Funding rounds

- Series B, Mar 9, 2021, $0.4M — TOHOKU University Venture Partners
- Series B, Sep 16, 2020, $3.1M — University of Tokyo Edge Capital Partners, Toshiba Corporation
- Series A, Sep 7, 2018, $1.8M — University of Tokyo Edge Capital Partners
- Seed, Mar 12, 2018 — University of Tokyo Edge Capital Partners

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Seed, Series A, Series B
- Toshiba Corporation — Series B
- TOHOKU University Venture Partners (https://capitalatlas.ai/funds/tohoku-university-venture-partners) — Series B